# mFOLFOX6 + Bevacizumab + PD-1 Monoclonal Antibody Vs. mFOLFOX6 in Locally Advanced pMMR/MSS CRC

> **NCT06791512** · PHASE3 · RECRUITING · sponsor: **Jun Huang** · enrollment: 166 (estimated)

## Conditions studied

- Colorectal Cancer (CRC)
- pMMR/MSS Adenocarcinoma of the Colon or Rectum

## Interventions

- **DRUG:** mFOLFOX6 + Bevacizumab + PD-1 monoclonal antibody
- **DRUG:** mFOLFOX6

## Key facts

- **NCT ID:** NCT06791512
- **Lead sponsor:** Jun Huang
- **Sponsor class:** OTHER
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** RECRUITING
- **Start date:** 2025-01-18
- **Primary completion:** 2030-12-31
- **Final completion:** 2031-12-31
- **Target enrollment:** 166 (ESTIMATED)
- **Last updated:** 2025-12-24


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT06791512

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT06791512, "mFOLFOX6 + Bevacizumab + PD-1 Monoclonal Antibody Vs. mFOLFOX6 in Locally Advanced pMMR/MSS CRC". Retrieved via AI Analytics 2026-06-03 from https://api.ai-analytics.org/clinical/NCT06791512. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*